{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:55:27Z","timestamp":1772038527316,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment optimization may require dosing flexibility. The Phase 3 JADE REGIMEN trial (NCT03627767) evaluated maintenance of abrocitinib 200\u2009mg\u2010induced response in patients with moderate\u2010to\u2010severe atopic dermatitis (AD) randomly assigned to subsequent maintenance with continuous\u2010dose abrocitinib (200\u2009mg), reduced\u2010dose abrocitinib (100\u2009mg) or placebo. Maintenance with continuous\u2010dose abrocitinib was associated with a stronger prevention of disease flares, but also with a higher occurrence of adverse events, compared with the reduced dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This post hoc analysis of JADE REGIMEN aimed to identify predictors of not flaring during the maintenance period and to generate tools that can be used to assess probability of not flaring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were analysed from patients who responded to abrocitinib 200\u2009mg induction therapy (12\u2009weeks) and were randomly assigned to receive abrocitinib (200\u2009mg or 100\u2009mg) or placebo in the 40\u2010week maintenance period. Demographic and baseline disease characteristics and level of response to induction were evaluated for association with not flaring using logistic regression. Parameters with a significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.15) interaction with the treatment arm were fitted into a multivariable regression model, which was used to assess probability of not flaring.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Lower percentage body surface area affected at baseline (<jats:italic>p<\/jats:italic>\u2009=\u20090.09), absence of prior exposure to systemic agents (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) and greater percentage change in EASI from baseline to randomization (<jats:italic>p\u2009&lt;<\/jats:italic>\u20090.001) were identified as predictors of not flaring with abrocitinib. In both abrocitinib arms, percentage change in EASI from baseline to end of induction (Week 12) was the major contributor to the probability of not flaring in the maintenance period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Maintenance of response using reduced\u2010dose abrocitinib 100\u2009mg may be feasible for patients with lower baseline disease severity and strong response to abrocitinib 200\u2009mg induction treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.20095","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T11:40:09Z","timestamp":1715859609000},"page":"2130-2138","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing maintenance therapy in responders to abrocitinib induction: A post hoc analysis of JADE REGIMEN"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3770-1743","authenticated-orcid":false,"given":"J. P.","family":"Thyssen","sequence":"first","affiliation":[{"name":"Bispebjerg Hospital University of Copenhagen  Copenhagen Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3686-7805","authenticated-orcid":false,"given":"J. I.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"George Washington University School of Medicine and Health Services  Washington District of Columbia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ruano","sequence":"additional","affiliation":[{"name":"IMIBIC\/Reina Sofia University Hospital, University of C\u00f3rdoba  C\u00f3rdoba Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"A.","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center  Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Gubelin","sequence":"additional","affiliation":[{"name":"Centro Medico Skinmed, Las Condes, Regi\u00f3n Metropolitana, Chile and Universidad de los Andes  Santiago Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"E. L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University  Portland Oregon USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Weidinger","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig\u2010Holstein  Kiel Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Valdez","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. K.","family":"Terry","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Biswas","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"G\u00fcler","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Istanbul Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Feeney","sequence":"additional","affiliation":[{"name":"Pfizer Ltd.  Tadworth, Surrey UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.10.039"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.038"},{"key":"e_1_2_11_4_1","volume-title":"Cibinqo 100\u2009mg film\u2010coated tablets. Summary of product characteristics","year":"2021"},{"key":"e_1_2_11_5_1","article-title":"Japan's MHLW approves Pfizer's Cibinqo\u00ae (abrocitinib) for adults and adolescents with moderate to severe atopic dermatitis","author":"Pfizer Inc","year":"2021","journal-title":"News Release Published"},{"key":"e_1_2_11_6_1","volume-title":"Summary of product characteristics (SmPC)","author":"Cibinqo\u00ae (abrocitinib)","year":"2021"},{"key":"e_1_2_11_7_1","volume-title":"Cibinqo (abrocitinib) tablets, for oral use. Prescribing information","year":"2022"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.075"},{"key":"e_1_2_11_9_1","volume-title":"Encyclopedia of statistical sciences, volume 6: multivariate analysis to Plackett and Burman designs","author":"Banks J","year":"1985"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S229667"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2060822"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00618-3"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","unstructured":"SimpsonEL SilverbergJI NosbaumA WinthropK Guttman\u2010YasskyE HoffmeisterKM et\u00a0al.Safety of abrocitinib in 3582 patients with monderate\u2010to\u2010severe atopic dermatitis with over 900 patients exposed for almost 2\u2009years. Presented at EADV 2022: Milan Italy; September 7\u201310 2022. Abstract 2851.","DOI":"10.1093\/bjd\/ljac140.025"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18643"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08768-3"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.03.019"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12049"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17541"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.20095","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T23:23:48Z","timestamp":1741735428000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.20095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/jdv.20095"],"URL":"https:\/\/doi.org\/10.1111\/jdv.20095","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]},"assertion":[{"value":"2023-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}